Lawrence Steinman

Publication Details

  • Interferon-beta exacerbates Th17-mediated inflammatory disease TRENDS IN IMMUNOLOGY Axtell, R. C., Raman, C., Steinman, L. 2011; 32 (6): 272-277


    Interferon (IFN)-? is the treatment most often prescribed for relapsing-remitting multiple sclerosis (RRMS). 30-50% of MS patients, however, do not respond to IFN-?. In some cases, IFN-? exacerbates MS, and it consistently worsens neuromyelitis optica (NMO). To eliminate unnecessary treatment for patients who are non-responsive to IFN-?, and to avoid possible harm, researchers are identifying biomarkers that predict treatment outcome before treatment is initiated. These biomarkers reveal insights into the mechanisms of disease. Recent discoveries on human samples from patients with RRMS, NMO, psoriasis, rheumatoid arthritis, systemic lupus erythematosus and ulcerative colitis, indicate that IFN-? is ineffective and might worsen clinical status in diverse diseases when a Th17 immune response is prominent.

    View details for DOI 10.1016/

    View details for Web of Science ID 000291904500005

    View details for PubMedID 21530402

Stanford Medicine Resources:

Footer Links: